FH
Foghorn Therapeutics Inc.
FHTX · NASDAQ
$4.67 -1.89% (-$0.09)
1M -22.60%
Market Cap $283.6M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
8 /100
Expensive P/S 7.72x
P/E N/A
EV/FFO N/A
Growth
96 /100
Growing Rev. growth 17.14%
EPS growth N/A
Book val. growth N/A
Profitability
17 /100
Weak Gross margin 42.73%
FCF margin 232.31%
Net margin 175.78%
Quality
3 /100
Poor ROIC 44.00%
Asset turnover 0.18x
ROA 31.75%
Debt
100 /100
Low Current ratio 3.36x
Debt/Equity N/A
Debt/Assets N/A
Stability
31 /100
Unstable Beta 2.86x
Profitable years 0
Rev. volatility 56.38%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na FHTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Adrian H. Gottschalk
Employees
106
Headquarters
Watertown
Nadcházející události
04 LIS
Earnings
Upcoming earnings report